This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Various				
Autoimmune disease; inflammation	Phosphoinositide 3-kinase-γ (PI3Kγ)	*In vitro*, cell culture and mouse studies suggest highly selective inhibitors of PI3Kγ could help treat inflammation and autoimmune diseases. *In vitro* screening and optimization led to the development of CZC24832, a small molecule inhibitor that is at least 100 times more selective for PI3Kγ over the other PI3K isoforms. In cell culture, CZC24832 decreased differentiation of proinflammatory T helper type 17 (Th17) cells compared with vehicle. In a mouse model of collagen-induced arthritis, CZC24832 lowered bone and cartilage destruction by 53% compared with vehicle. Next steps at Cellzome AG include using the *in vitro* screening platform to identify additional highly selective kinase inhibitors. Cellzome said it discontinued CZC24832 for strategic reasons. *SciBX* 5(20); doi:10.1038/scibx.2012.533 Published online May 17, 2012	Unpatented; licensing status undisclosed	Bergamini, G. *et al. Nat. Chem. Biol.*; published online April 29, 2012; doi:10.1038/nchembio.957 **Contact:** Gitte Neubauer, Cellzome AG, Heidelberg, Germany e-mail: gitte.neubauer@cellzome.com